Calprotectin in the risk stratification of patients with acute dyspnoea in the emergency department

Abstract Acute dyspnoea is one of the most common presenting symptoms in the emergency department (ED) and has a variety of underlying causes. Calprotectin is a neutrophil activation marker associated with adverse outcomes in acute cardiovascular and infectious diseases. However, the usefulness of c...

Full description

Saved in:
Bibliographic Details
Main Authors: Martin Wollmer, Torgny Wessman, Anders Larsson, Anna C. Nilsson, Olle Melander, Toralph Ruge
Format: Article
Language:English
Published: Nature Portfolio 2025-06-01
Series:Scientific Reports
Subjects:
Online Access:https://doi.org/10.1038/s41598-025-07741-9
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849433098388766720
author Martin Wollmer
Torgny Wessman
Anders Larsson
Anna C. Nilsson
Olle Melander
Toralph Ruge
author_facet Martin Wollmer
Torgny Wessman
Anders Larsson
Anna C. Nilsson
Olle Melander
Toralph Ruge
author_sort Martin Wollmer
collection DOAJ
description Abstract Acute dyspnoea is one of the most common presenting symptoms in the emergency department (ED) and has a variety of underlying causes. Calprotectin is a neutrophil activation marker associated with adverse outcomes in acute cardiovascular and infectious diseases. However, the usefulness of calprotectin in the risk stratification of patients with acute dyspnoea is unknown. The objectives were to, in unselected patients presenting to the ED with acute dyspnoea, investigate the association between (1) calprotectin and 90-day mortality, (2) calprotectin and 90-mortality in subgroups of patients with cardiovascular disease or pneumonia, and (3) calprotectin and illness severity. Single-centre observational cohort study from a university hospital in southern Sweden. A total of 1186 patients from the original Acute Dyspnoea Study, were included. Patients were followed for discharge diagnosis and mortality. Calprotectin concentration was measured in plasma samples collected at the ED. Mean age was 72 years and 56% were women. During follow-up, 143 patients died. In multivariate Cox regression for 90-day mortality, calprotectin in the highest quartile (> 0.96 mg/L) compared to the lowest quartile (< 0.27 mg/L) was associated with a hazard ratio of 2.71 (95% confidence interval 1.39–5.26, p < 0.01). The association with mortality remained significant in the subgroup of patients with acute cardiovascular disease (N = 205, p < 0.01). There was no statistically significant difference in median calprotectin values between survivors and non-survivors with pneumonia (1.62 vs. 1.31, p = 0.155). Multivariate linear regression showed a strong positive correlation between calprotectin and illness severity (respiratory rate ≥ 29 or oxygen saturation ≤ 90%, p < 0.001). In conclusion, calprotectin was associated with 90-day mortality and correlated strongly with illness severity. This indicates that measurement of calprotectin at admission could improve clinical risk stratification of the acute dyspnoeic ED patient. Clinical trial number: Not applicable.
format Article
id doaj-art-a95ea197ecf249d68306ba880521b751
institution Kabale University
issn 2045-2322
language English
publishDate 2025-06-01
publisher Nature Portfolio
record_format Article
series Scientific Reports
spelling doaj-art-a95ea197ecf249d68306ba880521b7512025-08-20T03:27:10ZengNature PortfolioScientific Reports2045-23222025-06-011511910.1038/s41598-025-07741-9Calprotectin in the risk stratification of patients with acute dyspnoea in the emergency departmentMartin Wollmer0Torgny Wessman1Anders Larsson2Anna C. Nilsson3Olle Melander4Toralph Ruge5Department of Emergency and Internal Medicine, Skåne University HospitalDepartment of Emergency and Internal Medicine, Skåne University HospitalDepartment of Medical Sciences, Uppsala UniversityDepartment of Infectious Disease Medicine, Skåne University HospitalDepartment of Emergency and Internal Medicine, Skåne University HospitalDepartment of Emergency and Internal Medicine, Skåne University HospitalAbstract Acute dyspnoea is one of the most common presenting symptoms in the emergency department (ED) and has a variety of underlying causes. Calprotectin is a neutrophil activation marker associated with adverse outcomes in acute cardiovascular and infectious diseases. However, the usefulness of calprotectin in the risk stratification of patients with acute dyspnoea is unknown. The objectives were to, in unselected patients presenting to the ED with acute dyspnoea, investigate the association between (1) calprotectin and 90-day mortality, (2) calprotectin and 90-mortality in subgroups of patients with cardiovascular disease or pneumonia, and (3) calprotectin and illness severity. Single-centre observational cohort study from a university hospital in southern Sweden. A total of 1186 patients from the original Acute Dyspnoea Study, were included. Patients were followed for discharge diagnosis and mortality. Calprotectin concentration was measured in plasma samples collected at the ED. Mean age was 72 years and 56% were women. During follow-up, 143 patients died. In multivariate Cox regression for 90-day mortality, calprotectin in the highest quartile (> 0.96 mg/L) compared to the lowest quartile (< 0.27 mg/L) was associated with a hazard ratio of 2.71 (95% confidence interval 1.39–5.26, p < 0.01). The association with mortality remained significant in the subgroup of patients with acute cardiovascular disease (N = 205, p < 0.01). There was no statistically significant difference in median calprotectin values between survivors and non-survivors with pneumonia (1.62 vs. 1.31, p = 0.155). Multivariate linear regression showed a strong positive correlation between calprotectin and illness severity (respiratory rate ≥ 29 or oxygen saturation ≤ 90%, p < 0.001). In conclusion, calprotectin was associated with 90-day mortality and correlated strongly with illness severity. This indicates that measurement of calprotectin at admission could improve clinical risk stratification of the acute dyspnoeic ED patient. Clinical trial number: Not applicable.https://doi.org/10.1038/s41598-025-07741-9Emergency service, hospitalLeukocyte L1 antigen complexBiomarkersDyspneaCommunicable diseasesMortality
spellingShingle Martin Wollmer
Torgny Wessman
Anders Larsson
Anna C. Nilsson
Olle Melander
Toralph Ruge
Calprotectin in the risk stratification of patients with acute dyspnoea in the emergency department
Scientific Reports
Emergency service, hospital
Leukocyte L1 antigen complex
Biomarkers
Dyspnea
Communicable diseases
Mortality
title Calprotectin in the risk stratification of patients with acute dyspnoea in the emergency department
title_full Calprotectin in the risk stratification of patients with acute dyspnoea in the emergency department
title_fullStr Calprotectin in the risk stratification of patients with acute dyspnoea in the emergency department
title_full_unstemmed Calprotectin in the risk stratification of patients with acute dyspnoea in the emergency department
title_short Calprotectin in the risk stratification of patients with acute dyspnoea in the emergency department
title_sort calprotectin in the risk stratification of patients with acute dyspnoea in the emergency department
topic Emergency service, hospital
Leukocyte L1 antigen complex
Biomarkers
Dyspnea
Communicable diseases
Mortality
url https://doi.org/10.1038/s41598-025-07741-9
work_keys_str_mv AT martinwollmer calprotectinintheriskstratificationofpatientswithacutedyspnoeaintheemergencydepartment
AT torgnywessman calprotectinintheriskstratificationofpatientswithacutedyspnoeaintheemergencydepartment
AT anderslarsson calprotectinintheriskstratificationofpatientswithacutedyspnoeaintheemergencydepartment
AT annacnilsson calprotectinintheriskstratificationofpatientswithacutedyspnoeaintheemergencydepartment
AT ollemelander calprotectinintheriskstratificationofpatientswithacutedyspnoeaintheemergencydepartment
AT toralphruge calprotectinintheriskstratificationofpatientswithacutedyspnoeaintheemergencydepartment